The OSCAR for cardiovascular disease prevention in chronic kidney disease goes to blood pressure control

Nephropathy progression is slowed and cardiovascular events reduced in patients with stage 3 or higher chronic kidney disease when blood pressure is controlled using combinations of renin┬ľangiotensin system (RAS) blockers with dihydropyridine calcium channel blockers or diuretics. We discuss a trial comparing high-dose RAS blockade with lower-dose RAS blockade combined with a dihydropyridine calcium channel blocker. The primary outcome was cardiovascular events. The combination group had better blood pressure control and fewer total events.

Read 59 times

Last modified on Thursday, 10 January 2013 09:30

Scroll to Top